RxDoctor Payments Data

Renee Chisum

Family · San Antonio, TXNPI 1568967008

Payments from drug & device makers

$29,552in general payments, 2019–2025

Across 1,418 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Novo Nordisk$3K
  • Ascendis Pharma Endocrinology Inc$2K
  • Lilly USA, LLC$2K
  • Dexcom, Inc.$2K
  • AstraZeneca$2K
  • plus $16K from 49 others

What the payments were for

  • Travel & lodging$1,4895%
  • Food & beverage$26,09895%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,552 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide630$935,554
MounjaroTirzepatide507$642,916
KorlymMifepristone11$572,313
JardianceEmpagliflozin324$419,224
FarxigaDapagliflozin Propanediol291$337,964
AfrezzaInsulin Regular, Human100$305,088
TrulicityDulaglutide178$269,811
Humalog Kwikpen U-200Insulin Lispro57$215,487
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7112$154,814
Tresiba Flextouch U-200Insulin Degludec42$86,272
VascepaIcosapent Ethyl87$71,832
ProliaDenosumab42$70,229
Tresiba Flextouch U-100Insulin Degludec88$69,496
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog71$64,191
TymlosAbaloparatide12$55,810

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog, Fiasp$2,608$1,025,124711 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$2,092$938,276753 claims
Corcept TherapeuticsKorlym$797$572,31311 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$1,438$498,888394 claims
AstraZenecaFarxiga$1,641$337,964291 claims
Mannkind CorporationAfrezza$1,259$305,088100 claims
AmgenProlia, Evenity (2 Syringes)$983$114,41959 claims
Radius Health, Inc.Tymlos$1,006$55,81012 claims
MerckJanumet Xr$87$25,54923 claims
Cequr CorporationCequr Simplicity$753$22,86832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →